Treatment of Dilated Cardiomyopathies with β-adrenergic Blocking Agents

  • M. R. Bristow
Conference paper


Anti-adrenergic therapy with β-adrenergic blocking agents has proved to be effective in the medical treatment of various dilated cardiomyopathies, including idiopathic, valvular and ischemic subtypes. This report will summarize the effects of β-blocker treatment on the dilated cardiomyopathy phenotype, as well as on clinical parameters.


Chronic Heart Failure Dilate Cardiomyopathy Idiopathic Dilate Cardiomyopathy Myocardial Gene Expression Myocyte Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Epstein SE, Braunwald E (1968) Inhibition of the adrenergic nervous system in the treatment of angina pectoris. Med Clin North Am 52:1031–1039PubMedGoogle Scholar
  2. 2.
    Mann DL, Kent RL, Parsons B, Cooper IV G (1992) Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 85:790–804PubMedCrossRefGoogle Scholar
  3. 3.
    Matsui T, Hajjar RJ, Kang JX, Rosenzweig A (1997) Norepinephrine directly induces apoptosis in neonatal rat myocytes. J Am Coll Cardiol 29 [Suppl 2]:230AGoogle Scholar
  4. 4.
    Communal C, Singh K, Pimentai DR, Colucci WS (1997) The ß-adrenergic pathway mediates norepinephrine-stimulated apoptosis in vitro in adult rat cardiac myocytes. Circulation 96 [Suppl I]:117Google Scholar
  5. 5.
    Geng YJ, Ishikawa Y, Vatner DE, Wagner TE, Bishop SP, Vatner SF, Homcy CJ (1996) Overexpression of Gsα accelerates programmed death (apoptosis) of myocardiocytes in transgenic mice. Circulation [Suppl 1] 94:1640Google Scholar
  6. 6.
    Bishopric NH, Sato B, Webster KA (1992) ß-adrenergic regulation of a myocardial actin gene via a cyclic AMP-independent pathway. J Biol Chem 267:20932–20936PubMedGoogle Scholar
  7. 7.
    Kariya K, Karns LR, Simpson PC (1991) Expression of a constitutively activated mutant of the ß-isozyme of protein kinase C in cardiac myocytes stimulates the promoter of the ß-myosin heavy chain isogene. J Biol Chem 266:10023–10026PubMedGoogle Scholar
  8. 8.
    Iwaki K, Sukhatme VP, Shubeita HE, Chien KR (1990) α-and ß-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. J Biol Chem 265:13809–13817PubMedGoogle Scholar
  9. 9.
    Lowes BD, Minobe WA, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, Badesch DB, Groves BM, Gilbert EM, Bristow MR (1997) Changes in gene expression in the intact human heart: down-regulation of α-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 100:2315–2324PubMedCrossRefGoogle Scholar
  10. 10.
    Bristow MR, Gilbert EM, Lowes BD, Minobe W, Shakar S, Quaife RA, Abraham WT (1997) Changes in myocardial gene expression associated with ß-blocker-related improvement in ventricular systolic function. Circulation 96 [Suppl I]:92Google Scholar
  11. 11.
    Eichhorn EJ, Bristow MR (1996) Medical therapy can improve the biologic properties of the chronically failing heart: A new era in the treatment of heart failure. Circulation 94:2285–2296PubMedCrossRefGoogle Scholar
  12. 12.
    Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I (1975) Effect of chronic betaadrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37:1022–1036PubMedCrossRefGoogle Scholar
  13. 13.
    Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O’Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, and Bristow MR (1990) Chronic ß-blockervasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: A double-blind, randomized study of bucindolol versus placebo. Am J Med 88:223–229PubMedCrossRefGoogle Scholar
  14. 14.
    Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield B, Deitchman D, Brown M, Willard JE, Grayburn PA (1990) Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure: improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 82:473–483PubMedCrossRefGoogle Scholar
  15. 15.
    Wisenbaugh T, Katz I, Davis J, Essop R, Skoularigis J, Middlemost S, Rothlisberger C, Skudicky D, Sareli P (1993) Long-term (3 month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Calrdiol 21:1094–1100CrossRefGoogle Scholar
  16. 16.
    Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR (1994) Effect of metoprolol on myocardial function and energetics in patients with non-ischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 24:1310–1320PubMedCrossRefGoogle Scholar
  17. 17.
    Glass MG, Fueihan F, Liao R, Lincolf AM, Chapados R, Hamlin R, Apstein CS, Allen PD, Ingwall JS, Hajjar R, Cory CR, O’Brien PJ, Gwathmey JK (1993) Differences in cardioprotective efficacy of adrenergic receptor antagonists in an animal model of dilated cardiomyopathy: Effects on gross morphology, global cardiac function, and twitch force. Circ Res 73:1077–1089PubMedCrossRefGoogle Scholar
  18. 18.
    Tsutsui H, Spinale FG, Nagatsu M, Sehmid PG, Ishihara K, DeFreyte G, Cooper G, Carabello BA (1994) Effects of chronic β-adrenergic blockade on the left ventricular and cardiocyte abnormalities of chronic canine mitral regurgitation. J Clin Invest 93:2639–2648PubMedCrossRefGoogle Scholar
  19. 19.
    Woodley SL, Gilbert EM, Anderson JL, O’Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R, Bristow MR (1991) β-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 84:2426–2441PubMedCrossRefGoogle Scholar
  20. 20.
    Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger R, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure Circulation 94:2807–2816Google Scholar
  21. 21.
    Bristow MR, O’Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker M, Marshall G, Kelly P, Deitchman D, Anderson JL, for the Bucindolol Investigators (1994) Dose-response of chronic ß-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 89:1632–1642PubMedCrossRefGoogle Scholar
  22. 22.
    Bristow MR (1996) Effect of carvedilol on survival and hospitalization in patients with ischemic or non-ischemic cardiomyopathy. Circulation 94 [Suppl] I–338CrossRefGoogle Scholar
  23. 23.
    Quaife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K. Olsen SL, Bristow MR (1996) Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol 78:779–784PubMedCrossRefGoogle Scholar
  24. 24.
    Australia-New Zealand Heart Failure Research Collaborative Group (1995) Effects of carvedilol, a vasodilator-ß-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92:212–218CrossRefGoogle Scholar
  25. 25.
    Australia-New Zealand Heart Failure Research Collaborative Group (1997) Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease. Lancet 349:375–380CrossRefGoogle Scholar
  26. 26.
    Hall SA, Cigarroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ (1995) Time course of improvement in left ventricular function, mass, and geometry in patients with congestive heart failure treated with ß-adrenergic blockade. J Am Coll Cardiol 25:1154–1161PubMedCrossRefGoogle Scholar
  27. 27.
    Lowes BD, Gill EA, Rodriguez-Larrain J, Abraham WT, Bristow MR, Gilbert EM (1996) Carvedilol is associated with a reversal of remodeling in chronic heart failure. Circulation 94:I–407Google Scholar
  28. 28.
    CIBIS Investigator and Committees (1994) A randomized trial of beta-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90:1765–1773CrossRefGoogle Scholar
  29. 29.
    Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Johnson M, Silver MA, Gilbert EM, Hjalmarson A (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342:1441–1446PubMedCrossRefGoogle Scholar
  30. 30.
    Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the US Carvedilol Heart Failure Study Group (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334:1349–1355PubMedCrossRefGoogle Scholar
  31. 31.
    Engelmeier RS, O’Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM (1985) Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial. Circulation 72:536–546PubMedCrossRefGoogle Scholar
  32. 32.
    Pollock SG, Lystash J, Tedesco C, Craddock G, Smucker ML (1990) Usefulness of bucindolol in congestive heart failure. Am J Cardiol 66:603–607PubMedCrossRefGoogle Scholar
  33. 33.
    Metra M, Nardi M, Giubbini R, Dei Cas L (1994) Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 24:1678–1687PubMedCrossRefGoogle Scholar
  34. 34.
    Olsen SL, Gilbert EM, Renlund DG, Mealey PC, Taylor DO, Yanowitz FD, Bristow M (1995) Carvedilol improves left ventricular function and symptoms in heart failure: A double-blind randomized study. J Am Coll Cardiol 25:1225–1231PubMedCrossRefGoogle Scholar
  35. 35.
    Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, Levin HR, Neuberg GW, DeLong G, Packer M (1995) Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure. Circulation 92:1499–1506PubMedCrossRefGoogle Scholar
  36. 35.
    Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH, for the PRECISE Study Group (1996) Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE Trial. Circulation 94:2793–2799PubMedCrossRefGoogle Scholar
  37. 36.
    Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger S, Hershberger RE, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Younj ST. Holcslaw TL, Lukas MA, for the US Carvedilol Heart Failure Study Group (1996) Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 94:2800–2806PubMedCrossRefGoogle Scholar
  38. 37.
    O’Connell JB, Bristow MR (1994) Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 13:S107–S112PubMedGoogle Scholar
  39. 38.
    Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR (1996) Comparative hemodynamic, LV functional, and antiadrenergic effects of chronic treatment with metoprolol vs. carvedilol in the failing heart. Circulation 94:2817–2825Google Scholar
  40. 39.
    Weber KT, Janicki JS (1985) Cardiopulmonary exercise testing for evaluation of chronic cardiac failure. Am J Cardiol 55:22A–31APubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 1998

Authors and Affiliations

  • M. R. Bristow

There are no affiliations available

Personalised recommendations